Davide Caimmi

Country flagFrance

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Background Anaphylaxis is a serious systemic hypersensitivity reaction that requires immediate recognition and prompt administration of epinephrine/adrenaline. The present study aimed to assess the appropriateness of epinephrine/adrenaline use in children identified as allergic by physicians in the emergency department (ED) at the time of the reaction, and to identify factors that are possibly associated with epinephrine/adrenaline administration, auto‐injector prescription, and further referral to an allergist. Methods We performed a retrospective cross‐sectional study at the pediatric ED of the University Hospital of Montpellier, France. We included all consecutive children who attended the ED between 2016 and 2020 with an allergy‐related diagnosis at discharge. Results We included 1056 allergy‐related visits, including 224 (21.2%) with a diagnosis of anaphylaxis at discharge; only 17.0% of them received an epinephrine/adrenaline injection, and 57.1% consulted an allergist after the acute episode. An auto‐injector was prescribed to 63 (28.1%) patients at discharge from the ED. Besides the severity of the clinical presentation, factors associated with a guidelines‐based management of the anaphylactic reaction and with an increased administration rate of epinephrine/adrenaline included presence of asthma symptoms and presence of extended skin reactions. Conclusions Our study underlines persistent gaps in the management of pediatric anaphylaxis in ED, focusing on hereby identified levers. By disseminating current knowledge and guidelines on anaphylaxis and allergies, specialists could work together with emergency physicians to establish effective management algorithms and improve anaphylaxis management and care pathways for children experiencing allergic reactions, especially anaphylaxis. Trail Registration Clinical Trials, number NCT05112367.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Francesca Mori

-

ITALY
View details

Ricardo Madrigal-Burgaleta

Lecturer

Universidad Internacional de Andalucía

SPAIN
View details

Luciana Tanno

University Hospital of Montpellier

FRANCE
View details

Alessandra Vultaggio

section of biochemistry university of florence italy

ITALY
View details

Carmen Riggioni

-

SINGAPORE
View details

Pascal Demoly

-

FRANCE
View details

Francesca Mori

-

ITALY
View details

Joana Vitte

Associate Professor of Immunology

Université de Reims Champagne-Ardenne

FRANCE
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.